Trevi Therapeutics (TRVI) Total Liabilities (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Total Liabilities of $7.5 million for Q1 2026, down 0.9% year-over-year from $7.5 million in Q1 2025, and down 26.64% quarter-over-quarter from $10.2 million in Q4 2025.
Trevi Therapeutics (TRVI) Total Liabilities (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $7.5 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 0.9% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (down 0.9% YoY), while the FY2025 annual figure was $10.2 million, down 9.43% from the prior year.
- Total Liabilities for Q1 2026 stood at $7.5 million, down from $10.2 million in the prior quarter.
- The five-year high for Total Liabilities was $20.9 million in Q2 2022, with the low at $5.9 million in Q2 2023.
- The 5-year median for Total Liabilities is $9.8 million (2025), against an average of $11.1 million.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities sank 71.75% in 2023, then soared 64.18% in 2024.
- Trevi Therapeutics' Total Liabilities stood at $15.6 million in 2022, then slumped by 55.93% to $6.9 million in 2023, then jumped by 64.18% to $11.3 million in 2024, then declined by 9.43% to $10.2 million in 2025, then slipped by 26.64% to $7.5 million in 2026.
- Business Quant data shows TRVI's Total Liabilities at $7.5 million in Q1 2026, $10.2 million in Q4 2025, and $9.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 9.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.01 Mn |
| Mar 31, 2026 | 7.48 Mn |
| Dec 31, 2025 | 10.20 Mn |
| Sep 30, 2025 | 9.57 Mn |
| Jun 30, 2025 | 9.85 Mn |
| Mar 31, 2025 | 7.55 Mn |
| Dec 31, 2024 | 11.26 Mn |
| Sep 30, 2024 | 9.94 Mn |
| Jun 30, 2024 | 7.64 Mn |
| Mar 31, 2024 | 6.23 Mn |
| Dec 31, 2023 | 6.86 Mn |
| Sep 30, 2023 | 6.29 Mn |
| Jun 30, 2023 | 5.90 Mn |
| Mar 31, 2023 | 14.47 Mn |
| Dec 31, 2022 | 15.56 Mn |
| Sep 30, 2022 | 18.46 Mn |
| Jun 30, 2022 | 20.90 Mn |
| Mar 31, 2022 | 19.92 Mn |
| Dec 31, 2021 | 21.40 Mn |
| Sep 30, 2021 | 20.22 Mn |